Despite substantial progress in confronting the global HIV-1 epidemic since its inception in
the 1980s, better approaches for both treatment and prevention will be necessary to end the …

The latent viral reservoir is the critical barrier for the development of a cure for HIV-1
infection. Previous studies have shown direct antiviral activity of potent HIV-1 Env-specific …

Novel broadly neutralizing antibodies targeting HIV-1 hold promise for their use in the
prevention and treatment of HIV-1 infection. Pre-clinical results have encouraged the …

The engineered outer domain germline targeting version 8 (eOD-GT8) 60-mer nanoparticle
was designed to prime VRC01-class HIV-specific B cells that would need to be matured …

Broadly neutralizing antibodies (bNAbs) represent a promising approach to prevent and
treat HIV-1 infection. However, viral escape through mutation of the HIV-1 envelope …

In the absence of an effective and safe vaccine against HIV-1, the administration of broadly
neutralizing antibodies (bNAbs) represents a logical alternative approach to prevent virus …

An important class of HIV-1 broadly neutralizing antibodies, termed the VRC01 class, targets
the conserved CD4-binding site (CD4bs) of the envelope glycoprotein (Env). An engineered …

Toll-like receptor 7 (TLR7) agonist and PGT121 (broadly neutralizing antibody, bnAb)
administration previously delayed viral rebound and induced SHIV remission. We evaluated …

Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains
an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional …

A large array of broadly neutralizing antibodies (bnAbs) against HIV have been isolated and
described, particularly in the last decade. This continually expanding array of bnAbs has …